Sonova enters strategic alliance with French biotech company to treat hearing loss

In December last year, Sonova dished out almost EUR 5m to Sensorion, a French biotech company specialized in the treatment of hearing disorders. Now, the two companies are entering into a strategic partnership with the goal of improving diagnostics and treatment through genetic analysis.

Arnd Kaldowsk, CEO at Sonova | Photo: Sonova / PR/Daniel Hager Photography & Film

A French-Swiss alliance for hearing loss treatment has been formed.

In a press release, the French biotech company Sensorion announces that it has signed a deal with Swiss Sonova, the world's biggest manufacturer of hearing aids. Together, they want to develop new and improved hearing loss diagnoses, "thereby opening the way for improved care through a combination of advanced therapeutic interventions and traditional hearing aids," the statement reads.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs